No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TMDX240621P120000
- 2.15
- +0.65+43.33%
15min DelayClose May 31 15:59 ET
2.15High2.15Low
2.15Open1.50Pre Close5 Volume75 Open Interest120.00Strike Price1.08KTurnover55.48%IV-12.98%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry2.15Time Value100Contract SizeAmericanOptions Type-0.1385Delta0.0127Gamma104.92Leverage Ratio-0.0968Theta-0.0098Rho-14.53Eff Leverage0.0694Vega
Intraday
- 5D
- 1D
News
Insider Sale: Director David Weill Sells Shares of TransMedics Group Inc (TMDX)
TransMedics(TMDX.US) Director Sells US$168.99K in Common Stock
$TransMedics(TMDX.US)$ Director Weill David sold 1,193 shares of common stock on May 29, 2024 at an average price of $141.65 for a total value of $168.99K.Source: Announcement What is statement of cha
TransMedics(TMDX.US) Officer Sells US$2.83 Million in Common Stock
$TransMedics(TMDX.US)$ Officer Gordon Stephen sold 20,000 shares of common stock on May 29, 2024 at an average price of $141.4 for a total value of $2.83 million.Source: Announcement What is statement
The 3.9% Return This Week Takes TransMedics Group's (NASDAQ:TMDX) Shareholders Three-year Gains to 460%
Form 144 | TransMedics(TMDX.US) Director Proposes to Sell 168.98K in Common Stocks
SEC FILLINGS DISCLOSED/ May 29, $TransMedics(TMDX.US)$ Director Weill David intends to sell 1,193 shares of its common stock on May 29, with a total market value of approximately $168.98K. Weill Dav
Form 144 | TransMedics(TMDX.US) Officer Proposes to Sell 2.74 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 29, $TransMedics(TMDX.US)$ Officer Gordon Stephen intends to sell 20,000 shares of its common stock on May 29, with a total market value of approximately $2.74 million. G
Comments
Owning stocks isn't enough -- you must understand what these companies do. If you can't summarize their business in one sentence, you might not truly know them.
Here are the one-liners for each stock in my portfolio 🧐
1. $CrowdStrike(CRWD.US$ | Crowdstrike
• Their Falcon platform uses artificial AI and cloud technology to detect and respond to cyber threats by offering endpoint security, threat intelligence, and cyberattack response services.
2. $Snowflake(SNOW.US$ | Snowflake
• A cloud-...
Here are the one-liners for each stock in my portfolio 🧐
1. $CrowdStrike(CRWD.US$ | Crowdstrike
• Their Falcon platform uses artificial AI and cloud technology to detect and respond to cyber threats by offering endpoint security, threat intelligence, and cyberattack response services.
2. $Snowflake(SNOW.US$ | Snowflake
• A cloud-...
61
4
TransMedics Group's trend of growing ROCE and increasing capital employed suggests profitable reinvestment opportunities, potentially leading to a multi-bagger performance. The stock's solid return to shareholders over the last three years indicates investor recognition of these changes.
1
$Advanced Micro Devices(AMD.US$ was obvious to buy at $100 and many waited
$Celsius Holdings(CELH.US$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
$Celsius Holdings(CELH.US$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
9
3
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Read more
BH_6730 : Fantastic
眼观六路的沃勒 : Like
Master Corgi : Damn you miss out PANW
Dramericanjesus : Being able to read a financial statement is far more valuable.